Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

International journal of hematology - 1 Aug 2026

Izutsu Koji, Fujimoto Ayumi, Rai Shinya, Maruyama Dai, Ohmachi Ken, Yokohama Akihiko, Tsukasaki Kunihiro, Uchida Toshiki, Kuroda Junya, Choi Ilseung, Hidaka Michihiro, Ando Jun, Sakamoto Takashi, Kato Hisashi, Minami Hironobu, Yoshida Shinichiro, Yamamoto Matsuo, Gillings Mireille, Onogi Hiroshi, Takeuchi Kengo

Abstract excerpt

T follicular helper (TFH)-derived peripheral T-cell lymphomas (PTCLs) harbor frequent mutations in epigenetic regulators and are sensitive to epigenetic therapies. The histone deacetylase inhibitor tucidinostat demonstrated efficacy in relapsed/refractory PTCL, especially angioimmunoblastic T-cell lymphoma (AITL), in a phase IIb trial; however, the lack of TFH phenotyping has prevented assessment of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Histone Deacetylase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, T-Cell, Peripheral

Share to Phenotype

Share to Recurrence

Share to Treatment Outcome

Source

Identifiers

PMID: 42262647
DOI: 10.1007/s12185-026-04237-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.PMID 42262647Read ↗

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.Semantic proximity Read ↗

Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical RealitySemantic proximity Read ↗

Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.Semantic proximity Read ↗

The new biology of PTCL‐NOS and AITL: current status and future clinical impactSemantic proximity Read ↗

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.Semantic proximity Read ↗

Genetic Landscape and Classification of Peripheral T Cell Lymphomas.Semantic proximity Read ↗

Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.Semantic proximity Read ↗

Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.Semantic proximity Read ↗

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphomaSemantic proximity Read ↗

Update on peripheral T-cell lymphomas with T-helper phenotype: Are there too many subtypes?Semantic proximity Read ↗

Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: a multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression.Semantic proximity Read ↗

New insights in the pathogenesis of T-cell lymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.